PLUS THERAPEUTICS, Inc. Common Stock (PSTV)
Plus Therapeutics, Inc. (PSTV) is a clinical-stage biopharmaceutical company focused on developing targeted radiopharmaceuticals for the treatment of cancer. The company aims to leverage novel radioisotope-based therapies to improve outcomes for patients with difficult-to-treat tumors, utilizing advanced delivery platforms to enhance efficacy and minimize side effects.
Company News
CNSide Diagnostics, a subsidiary of Plus Therapeutics, secured a national agreement with UnitedHealthcare covering over 51 million people for its cerebrospinal fluid tumor cell diagnostic test, which has demonstrated high sensitivity and specificity in cancer diagnosis.
The leptomeningeal metastases market is projected to grow slowly due to rising cancer incidence and increasing central nervous system complications. Several emerging therapies like REYOBIQ and Paxalisib are expected to drive market development in the coming years.
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are these penny stocks to watch on your list this week? The post Penny Stocks To Buy Now? 4 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.